99% Purity Fenofibrate Pharmaceutical Triglyceride Fenofibrate Raw Material Powder Fenofibrate

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Fenofibrate
• Product Name: Fenofibrate
• Name: Fenofibrate Powder
• Appearance: off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antihyperlipidemic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 49562-28-9
• Mf: C20h21clo4
• MW: 360.83134
• Density: 1.177
• Melting Point: 80-81 C
• Boiling Point: 469.8 C at 760 Mmhg
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5 Ton/Month

Product Description

99% Purity Fenofibrate Pharmaceutical Triglyceride Fenofibrate Raw Material Powder Fenofibrate

 

Product Description

Product Details

Product Name	Fenofibrate
CAS No.	49562-28-9
MF	C20H21ClO4
MW	360.83134
Appearance and shape	Off-white powder

Fenofibrate is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates,it reduces both lowdensity lipoprotein (LDL) and very low density lipoprotein (VLDL) levels,as well as increasing highdensity lipoprotein (HDL) levels and reducing triglycerides level. It is used alone or along with statins in the treatment of hypercholesterolemia and hypertriglyceridemia.

Application & Function

Function
1.   Fenofibrate has significant clinical efficacy in the treatment of lipid abnormalities in diabetic patients.
2.   Fenofibrate has the effect of regulating blood lipid.
3.   Fenofibrate has anti-inflammatory and lowers fibrinogen levels.
4.   Fenofibrate has preventive neuroprotective effects.
Application
Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia.  Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus, and firstly indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy in Australia.  It also appears to be helpful in decreasing amputations of the lower legs in this same group of people.  Fenofibrate also has an off-label use as an added therapy of high blood uric acid levels in people who have gout.

Specification